Roxadustat in the Treatment of Anemia in Chronic Kidney Disease (CKD) Patients, Not on Dialysis, in Comparison to Darbepoetin Alfa
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 616 participants.
Also called NCT02021318
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 616 participants
- Registry
-
NCT02021318 -
2013-000951-42
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Austria, Belarus, Bulgaria, Croatia, Czechia, Finland, France, Georgia, Germany, Hungary, Ireland, Israel, Latvia, Montenegro, Netherlands, North Macedonia, Poland, Portugal, Romania, Russia, Serbia, Slovakia, Slovenia, Spain, Ukraine, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT02021318. Randomized; no masking; primary purpose treatment. Start 2014-03-12 (actual); primary completion 2018-03-23 (actual). Results posted on 2021-03-29.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Roxadustat in the Treatment of Anemia in Chronic Kidney Disease (CKD) Patients, Not on Dialysis, in Comparison to Darbepoetin Alfa
- Acronym
- Dolomites
- Condition
- Anemia in Chronic Kidney Disease in Non-dialysis Patients
- Intervention (Drug)
- Roxadustat
- Intervention (Drug)
- Darbepoetin alfa
- Lead sponsor
- Astellas Pharma Europe B.V.
- Collaborator
- Kyntra Bio
Record details
- Record id
cardio:ct-nct02021318- Content hash
51fc56e9c8e36cb60da9c40cb9a6302af9f14ad22f1a24c8afc8b57cd3f6fced